Advertisement
UK markets close in 6 hours 24 minutes
  • FTSE 100

    7,883.70
    +35.71 (+0.46%)
     
  • FTSE 250

    19,427.74
    +87.60 (+0.45%)
     
  • AIM

    744.20
    +1.08 (+0.15%)
     
  • GBP/EUR

    1.1678
    +0.0011 (+0.10%)
     
  • GBP/USD

    1.2473
    +0.0017 (+0.14%)
     
  • Bitcoin GBP

    49,241.71
    -1,610.45 (-3.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CRUDE OIL

    82.07
    -0.62 (-0.75%)
     
  • GOLD FUTURES

    2,394.10
    +5.70 (+0.24%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • DAX

    17,799.22
    +29.20 (+0.16%)
     
  • CAC 40

    8,028.04
    +46.53 (+0.58%)
     

Here's Why You Should Retain Genpact (G) in Your Portfolio

A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.

We believe Genpact Limited G, with a market cap of $7.2 billion and long-term (three-five years) expected earnings per share growth rate of 14%, is a stock investors should retain in their portfolio. Shares of the company have gained 4.7% over past three months.

Factors Supporting the Stock

Genpact is benefiting from a strong clientele worldwide. The company serves almost one fourth of the Global Fortune 500, including big names such as Citigroup C, Canon CAJ, Novartis NVS, Kraft Heinz and McKesson. Notably, revenues from Global Clients increased 14.5% year over year to $802 million in the first quarter of 2020.

ADVERTISEMENT

Genpact Limited Revenue (TTM)

Genpact Limited Revenue (TTM)
Genpact Limited Revenue (TTM)

Genpact Limited revenue-ttm | Genpact Limited Quote

Acquisitions, over time, have been an effective mode of expanding product portfolio and gaining new domain expertise for Genpact.  The November 2019 acquisition of Rightpoint Consulting builds on the capabilities gained from TandemSeven and Endeavour Software Technologies’ acquisitions, and places Genpact in a stronger position to help clients build new products and services, develop digital workspaces, and drive partner engagement.

To mitigate the impacts of the coronavirus outbreak on its business, Genpact has shifted to a work-from-home system and is focusing on improving operational delivery performance and productivity in a virtual work environment.

Some Risks

Genpact has a debt-laden balance sheet. Total debt at the end of first-quarter 2020 was $1.90 billion compared with $1.80 billion at the end of the prior quarter. The debt-to-capital ratio of 0.55 is higher than the industry’s 0.39 and the previous quarter’s 0.52. An increase in debt-to-capitalization ratio indicates higher risk of insolvency in challenging times.

Further, the company’s cash and cash equivalent of $402 million at the end of the first quarter was well below this debt level, underscoring that it doesn’t have enough cash to meet this debt burden. The cash level, however, can meet the short-term debt of $260 million.

Zacks Ranks

While Genpact, Citigroup and Novartiscarry a Zacks Rank #3 (Hold), Canon has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Citigroup Inc. (C) : Free Stock Analysis Report
 
Canon, Inc. (CAJ) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
Genpact Limited (G) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research